Next 10 |
home / stock / eprx:cc / eprx:cc news
Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo Canada NewsWire VICTORIA, BC , July 8, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnolo...
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024 Canada NewsWire Osteoarthritis ("OA") is the leading cause of disability in older adults. The U.S. Centers for Disease Control an...
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders Canada NewsWire VICTORIA, BC , June 6, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. (" Eupraxia " or the " Company ") (TSX: EPRX) (NASDAQ: EPRX), a cli...
Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024 Canada NewsWire VICTORIA, BC , June 5, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Compan...
Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis Canada NewsWire Eight of nine patients responding to the treatment, plus the encouraging safety data observed in the RESOLVE Phase 1b /2a trial o...
Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024 Canada NewsWire VICTORIA, BC , May 22, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (...
Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis Canada NewsWire Trial's first and second cohorts maintaining signs of potential efficacy out to 24 weeks Data from the second coh...
Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024 Canada NewsWire VICTORIA, BC , May 14, 2024 /CNW/ - Eupraxia Phar...
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update Canada NewsWire Eupraxia common shares now listed on the Nasdaq Capital Market ("Nasdaq") under the symbol "EPRX" Additional data from RESOLVE study evaluating EP-104GI for ...
Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board Canada NewsWire --Advisory Board to Provide Guidance for Company's Eosinophilic Esophagitis Clinical Program-- VICTORIA, BC , May 2, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc...
News, Short Squeeze, Breakout and More Instantly...
Eupraxia Pharmaceuticals Inc. Company Name:
EPRX:CC Stock Symbol:
TSXC Market:
Eupraxia Pharmaceuticals Inc. Website:
Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo Canada NewsWire VICTORIA, BC , July 8, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnolo...
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024 Canada NewsWire Osteoarthritis ("OA") is the leading cause of disability in older adults. The U.S. Centers for Disease Control an...
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders Canada NewsWire VICTORIA, BC , June 6, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. (" Eupraxia " or the " Company ") (TSX: EPRX) (NASDAQ: EPRX), a cli...